Comparison of Loading Strategies With Antiplatelet Drugs in Patients Undergoing Elective Coronary Intervention

Inclusion Criteria: * Patients with biomarker negative stable or unstable angina pectoris * Written informed consent * In women with childbearing potential a pregnancy test is obligatory Exclusion Criteria: * Age \< 18 years and \>80 years * ST-elevation MI * Elevated cardiac biomarkers * Subjects with known contraindications to clopidogrel treatment, which are hypersensitivity to the drug substance or any component of the product and active pathological bleeding such as peptic ulcer or intracranial hemorrhage and with known severe liver disease (Child Pugh Class C) * Subjects with known contraindications to prasugrel treatment, which are hypersensitivity to the drug substance or any component of the product, active pathological bleeding such as peptic ulcer or intracranial hemorrhage and a history of prior transient ischemic attack (TIA) or stroke and with known severe liver disease (Child Pugh Class C) * Chronic therapy on potent P2Y12 receptor inhibitors (ticagrelor, prasugrel) * Pre-treatment with a loading dose of either clopidogrel, prasugrel or ticagrelor * Simultaneous participation in another clinical trial that involves the administration of an investigational medicinal drug within 30 days prior to the start of this clinical trial * Major surgeries in the last 6 weeks and planned surgeries within the next 6 weeks (per decision of the treating physician) * Active bleeding * Known or persistent abuse of medication, drugs or alcohol * Current or planned pregnancy or…